Showing results (131-140 of 143) with videos related to
Sort By:
Pageof 15
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 6, 2025
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective AnalysisTakeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.Journal of Gastroenterology|August 20, 2025
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Cancer Medicine|February 15, 2026
Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical PracticeHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Journal of Gastroenterology and Hepatology|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA TrialTomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.Liver International : Official Journal of the International Association for the Study of the Liver|July 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCCKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 9, 2026
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World StudyHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Liver Cancer|June 3, 2026
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 10, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus BevacizumabKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 26, 2026
Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus TremelimumabTomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.Pageof 15